Analyst Research

Report Title Price
Provider : Reuters Investment Profile
Provider : Wright Reports
Provider : Thomson Reuters StreetEvents
Provider : GlobalData

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Medivir AB announces presentation of SVR12 results from a phase IIa study evaluating Simeprevir and Daclatasvir in Hepatitis C patients of genotype 1

Tuesday, 4 Mar 2014 12:15pm EST 

Medivir AB:Announces that study results from a phase IIa trial evaluating simeprevir have been presented at the 21th Conference on Retroviruses and Opportunistic Infections (CROI) on March 4 in Boston, USA.Says simeprevir is a once-daily protease inhibitor jointly developed by Janssen R&D Ireland and Medivir AB.Says it is also in combination with daclatasvir, an investigational once-daily NS5A inhibitor developed by Bristol -Myers Squibb, with and without ribavirin, in patients with hepatitis C (HCV) genotype 1 infection.Says data from the study demonstrate that sustained virologic response 12 weeks after the end of treatment (SVR12) was reached in 75 to 85 pct of treatment-naive patients and 65 to 95 pct of prior null responders with HCV genotype 1b after 12 or 24 weeks of treatment. 

Company Quote

-0.5 -0.69%
2 Oct 2015